1356483-58-3Relevant academic research and scientific papers
Development of [18F]AldoView as the First Highly Selective Aldosterone Synthase PET Tracer for Imaging of Primary Hyperaldosteronism
Sander, Kerstin,Gendron, Thibault,Cybulska, Klaudia A.,Sirindil, Fatih,Zhou, Junhua,Kalber, Tammy L.,Lythgoe, Mark F.,Kurzawinski, Tom R.,Brown, Morris J.,Williams, Bryan,?rstad, Erik
, p. 9321 - 9329 (2021/07/19)
The purpose of this study was to synthesize a fluorine-18 labeled, highly selective aldosterone synthase (hCYP11B2) inhibitor, [18F]AldoView, and to assess its potential for the detection of aldosterone-producing adenomas (APAs) with positron emission tom
METALLOENZYME INHIBITOR COMPOUNDS
-
Page/Page column 46, (2020/07/25)
Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
Development of Highly Selective Pyrimidine-Based Aldosterone Synthase (CYP11B2) Inhibitors
Sparks, Steven M.,Danger, Dana P.,Hoekstra, William J.,Leesnitzer, Tony,Schotzinger, Robert J.,Yates, Christopher M.,Becherer, J. David
supporting information, p. 1056 - 1060 (2019/06/25)
Excess aldosterone production and signaling are primary contributors to numerous cardiovascular disorders including primary aldosteronism and resistant hypertension. Recently, inhibition of aldosterone synthesis via the enzyme aldosterone synthase (CYP11B
METALLOENZYME INHIBITOR COMPOUNDS
-
Paragraph 0518; 0521; 0522, (2018/07/29)
Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
METALLOENZYME INHIBITOR COMPOUNDS
-
Paragraph 0322; 0325; 0326, (2018/07/29)
Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
Discovery of benzimidazole CYP11B2 inhibitors with in vivo activity in rhesus monkeys
Hoyt, Scott B.,Park, Min K.,London, Clare,Xiong, Yusheng,Tata, Jim,Bennett, D. Jonathan,Cooke, Andrew,Cai, Jiaqiang,Carswell, Emma,Robinson, John,MacLean, John,Brown, Lindsay,Belshaw, Simone,Clarkson, Thomas R.,Liu, Kun,Liang, Gui-Bai,Struthers, Mary,Cully, Doris,Wisniewski, Tom,Ren, Ning,Bopp, Charlene,Sok, Andrea,Cai, Tian-Quan,Stribling, Sloan,Pai, Lee-Yuh,Ma, Xiuying,Metzger, Joe,Verras, Andreas,McMasters, Daniel,Chen, Qing,Tung, Elaine,Tang, Wei,Salituro, Gino,Buist, Nicole,Kuethe, Jeff,Rivera, Nelo,Clemas, Joe,Zhou, Gaochao,Gibson, Jack,Maxwell, Carrie Ann,Lassman, Mike,McLaughlin, Theresa,Castro-Perez, Jose,Szeto, Daphne,Forrest, Gail,Hajdu, Richard,Rosenbach, Mark,Ali, Amjad
supporting information, p. 573 - 578 (2015/05/27)
We report the discovery of a benzimidazole series of CYP11B2 inhibitors. Hit-to-lead and lead optimization studies identified compounds such as 32, which displays potent CYP11B2 inhibition, high selectivity versus related CYP targets, and good pharmacokin
ALDOSTERONE SYNTHASE INHIBITORS
-
Page/Page column 41, (2012/02/05)
The invention involves compounds of structural Formula (I) and the pharmaceutically acceptable salts thereof. The compounds of the invention are effective at selectively inhibiting CYP11B2, and are therefore useful for the treatment or prophylaxis of disorders that are associated with elevated aldosterone levels, including, but not limited to, hypertension and heart failure.
